Toulouse Cedex 9

• DUMELEP trial - Durvalumab (MEDI4736)/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by percutaneous ablation … Recruiting
  2024-515768-30-01 4 2024-03-28 Hepatocellular carcinoma
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients Recruiting
  2024-513328-40-00 6 2024-03-25 Pyelonephritis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud … Recruiting
  2022-501408-81-01 4 2024-03-04 Covid-19
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) Recruiting
  2024-516402-32-00 5 2024-02-13 Adult patients with aHUS associated with HE and severe kidney involvem
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting
  2023-503965-48-00 1 2024-01-11 Advanced (unresectable or metastatic) human epidermal growth receptor
• FIRE Stones : Impact of Furosemide on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser : a … Recruiting
  2022-502890-40-00 5 2024-01-04 Destruction of kidney stones
• A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I … Recruiting
  2024-514101-65-00 4 2023-12-21 Multiple Myeloma
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 7 2023-12-01 participants with isolated methylmalonic acidemia (MMA) due to methylm
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l … Recruiting
  2023-504555-27-00 5 2023-11-28 Myelodysplastic syndrome (MDS)
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 4 2023-11-21 Low-grade serous ovarian cancer
• A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting
  2022-501057-36-00 5 2023-10-24 ANCA-associated vasculitis
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting
  2023-504845-30-00 7 2023-10-05 Solid malignancies
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul … Recruiting
  2022-502019-12-00 5 2023-09-14 acute myeloid leukemia
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma

Showing 385–408 of 893 trials